A Single-Dose and Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3372993 in Healthy Subjects and Patients With Alzheimer's Disease
Phase of Trial: Phase I
Latest Information Update: 07 Feb 2019
At a glance
- Drugs LY 3372993 (Primary)
- Indications Alzheimer's disease; Cognition disorders
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 19 Nov 2018 Planned End Date changed from 29 Oct 2021 to 7 Sep 2021.
- 19 Nov 2018 Planned primary completion date changed from 29 Oct 2020 to 7 Sep 2020.
- 19 Nov 2018 Status changed from not yet recruiting to recruiting.